Skip to main content
. Author manuscript; available in PMC: 2011 Oct 8.
Published in final edited form as: FEBS Lett. 2010 Sep 17;584(19):4259–4267. doi: 10.1016/j.febslet.2010.09.022

Figure 4. Akt inhibition by triciribine hydrate (TCN) reduces ADAM10 activation, total Akt, and phosphorylated Akt, in the presence of EGCG.

Figure 4

Various treatment conditions in SweAPP N2a cells are denoted as a-f and correspond to the following: a. no treatment, b. EGCG, c. TCN 5μM, d. TCN 1 μM + EGCG, e. TCN 5 μM + EGCG, f. TCN 50 μM + EGCG. EGCG was used at a concentration of 20 μM for all conditions unless otherwise indicated. (A) SweAPP N2a cells were treated with varying concentrations of Akt inhibitor (TCN) in the presence and absence of EGCG. Cell lysates were prepared and subjected to western analysis of ADAM10 maturation, total Akt, phospho-Akt (Ser473), and β-actin (internal control). (B) Densitometric analysis shows the ratio of active mature (mADAM10) to proform (pro-ADAM10) as indicated below the figure. One-way ANOVA revealed significant differences between TCN treated and control cells at concentrations of 5 and 10 μM (**P<0.01 with n = 3 for each condition) in the presence of EGCG. # represents the protein of interest compared to control without EGCG treatment. (C, D) Densitometric analysis was performed on total Akt and phospho-Akt (Ser473) and represented as percent of associated control (SweAPP N2a +/- EGCG) following treatment with TCN ± SEM (n = 3), * P<0.05 and ** P<0.01 of protein of interest compared to EGCG control, # represents the protein of interest compared to control without EGCG treatment. Significant differences between treated and control were present at concentrations of 5 and 10 μM for total Akt in the presence of EGCG only, while phospo-Akt was significantly reduced for all TCN concentrations in the presence and absence of EGCG.

HHS Vulnerability Disclosure